We assessed the effect of interleukin-9 (IL-9) on clonogenic maturation and cell-cycle status of hematopoietic progenitors of fetal (umbilical cord blood) and adult (bone marrow) origin. As a single agent IL-9 supported, in a concentrationdependent fashion, maturation of burst-forming unitserythroid (BFU-E) of adult and fetal origin. However, only % the number of adult BFU-E colonies developed, as did in response t o granulocyte-macrophage colony-stimulating factor (GM-CSF), and only 3/s the number developed as did in response t o IL-3. In contrast, the effect of IL-9 on fetal BFU-E colonies was equal t o that of GM-CSF and IL-3. Synergistic effects of IL-9 with low concentrations (0.1 ng/mL) of GM-CSF and IL-3 were seen on adult BFU-E colony formation, but no effect was apparent at higher concentrations (1.0 ng/mL). In contrast, using fetal cells, synergistic effects of IL-9 with low and high concentrations of GM-CSF and IL-3 were apparent. Addition of IL-9 t o plates containing fetal cells plus ANG ET AL' RECENTLY identified a novel human Y cytokine for which they proposed the designation "interleukin-9'' (IL-9). The factor was identified in conditioned medium from a human T-cell leukemia virus-ltransformed T-cell line, C5MJ2, that supported growth of the human megakaryoblastic leukemic cell line, M07E. Functional expression cloning in COS-1 cells identified a cDNA that encoded a protein with striking similarity to a murine growth factor for helper T-cell clones, designated T-cell growth factor P40.' The finding that IL-9 was mitogenic for at least one human myeloid leukemic cell line suggested the possibility that it might play a role in hematopoiesis.' Indeed, Donahue et aP observed that, in combination with erythropoietin (Epo), IL-9 supported clonogenic maturation of twofold to threefold more erythroid progenitors than appeared in medium a10ne.~ Studies by Namiki and Hara4 and Schaafsma et aI5 indicate that clonogenic maturation of hematopoietic progenitors can be affected not only by factors added to culture plates, but also by factors produced by mononuclear cells either added to the plates with the partially purified progenitors or present within developing colonies. Those studies suggested that this unwanted influence can be reduced by including in the cultures neutralizing antibody directed against the unwanted cytokines and growth factors. Indeed, if even low concentrations of erythroid "burst promotors" such as granulocyte-macrophage colony-stimulating factor (GM-CSF) were produced within culture dishes, this might interfere with the interpretation of studies of the effect of IL-9 on erythroid burst formation. Therefore, we performed experiments to further clarify the effect of IL-9 on clonogenic maturation, in which neutralizing antibodies were included in the relevant culture dishes. We also examined possible synergistic or additive effects of IL-9 with GM-CSF and IL-3, and using tritiated thymidine suicide studies examined the effect of IL-9 on cell cycle status. As has been demonstrated with Epo6.' and 1L-6,9 we observed that IL-9 has a much wider spectrum of action on fetal progenitors than on adult progenitors.
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GM-CSF and IL-3 not only resulted in more BFU-E colonies, but also in more multicentered ( 2 10 individual centers) colonies, and more cells per colony. IL-9 had a wider spectrum of action on progenitors of fetal origin than on progenitors of adult origin, supporting the generation of fetal multipotent colony-forming unit (CFU)-Mix and CFU-GM colonies. Incubation with IL-9 did not accelerate cycling of adult or fetal BFU-E, CFU-Mix, or CFU-GM t o the extent observed after incubation with IL-6. Thus, IL-9 primarily supported maturation of erythroid progenitors of adult origin, and its addition t o plates containing GM-CSF and IL-3 (1.0 ng/mL) did not result in maturation of additional clones. In contrast, IL-9 had a wider spectrum of action on fetal progenitors and, when combined with IL-3 and GM-CSF, resulted in clonogenic maturation of progenitors that did not undergo maturation after stimulation with IL-3 and GM-CSF.
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MATERIALS AND METHODS

Subjects.
Fetal blood was obtained from the placental end of the umbilical cord by direct needle puncture of the umbilical vein immediately after 13 healthy deliveries. Bone marrow was aspirated from 13 healthy adult volunteers. The studies were performed according to protocols approved by the University of Utah Institutional Review Board and informed consent was obtained from the participants.
Recombinant hematopoietic factors and monoclonal antigrowth factor antibodies. Purified recombinant human Epo (ChugaiUpjohn Inc, Rosemont, IL) had a specific activity of > 3 X 10s Uimg with a purity by sodium dodecyl sulfate polyacrylamide gel electrophoresis of greater than 99.7%. Purified recombinant IL-3, IL-6, GM-CSF, and G-CSF (R&D Systems, Minneapolis, MN) all had specific activities of > 4 x IO' Ulmg and were purified to greater than 95%. IL-9 was produced by COS cells transfected with the IL-9 cDNA, as previously described.' One-half maximal biologic activity (M07E proliferation assay) was obtained with a transfected COS cell supernatant dilution of 1:2,500. This concentration of IL-9 is referred to as 1 UlmL. The supernatant from COS cells not transfected with the IL-9 cDNA (mock-COS) was used as a control.
Antihuman GM-CSF and antihuman IL-3 neutralizing antibodies (R&D Systems) were raised in goats immunized with purified recombinant human GM-CSF and IL-3. At a concentration of 10 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From p,g/mL, anti-GM-CSF neutralized greater than 99% of the biologic activity of 0.5 ng/mL recombinant human GM-CSF in clonogenic assays. Anti-IL-3, at a concentration of 10 pg/mL, neutralized 80% of the biologic activity of 1.25 ngimL of recombinant human IL-3 in clonogenic assays.
To assess the effect of IL-9 on the cycling status of hematopoietic progenitors, adult or fetal cells (1 to 5 x 10VmL) were incubated in serum-free media (a MEM, HyClone, Logan UT; and 1% Nutradoma, Boehringer Mannheim, Indianapolis, IN) that contained either various concentrations of IL-9, or 5 ng IL-6/mL, as a positive control9 or a MEM or mock-COS in a MEM as negative controls. Three concentrations of IL-9 were tested: 0.2, 2.0, and 20.0 UlmL. Cells were incubated for 3.5 hours in a 5% CO, incubator, after which each cell suspension was divided into two equal aliquots. Tritiated thymidine of high specific activity (86 Ciimmol; Amersham International PLC, Amersham, UK) was added to one aliquot of each sample for an additional 20-minute incubation."
After the previously described 20-minute incubations, cells were washed twice and cultured (7 to 25 X lo3 cellsiml) in the presence of the combination of IL-3 (1 ng/mL), GM-CSF (1 ng/mL), G-CSF (1 ng/mL), and Epo (2 UlmL). Quadruplicate 1-mL culture dishes contained a MEM, 5 X m o m p-mercaptoethanol (Eastman Chemical Co, Rochester, NY), 30% fetal calf serum (HyClone), 1% bovine serum albumin (Sigma Chemicals, St Louis, MO), and 1.1% methylcellulose (Sigma). After 14 days of culture, colonies were categorized in situ as colony-forming unit (CFU)-GM-derived colonies if they contained no red elements and were composed of greater than 50 cells. They were categorized as burst-forming units-erythroid (BFU-E)-derived colonies if they were composed exclusively of red tightly clustered aggregates. The number of red tightly clustered centers per BFU-E-derived colony was also recorded. Colonies were categorized as CFU-Mix-derived colonies if they contained red tightly clustered aggregates plus nonred loosely arranged cells.
In other studies, we sought to evaluate the capacity of IL-9 as a single agent or in combination with GM-CSF and/or IL-3 to support clonal maturation of fetal and adult hematopoietic progenitors. In these studies, suspensions of fetal and adult cells were depleted of mature erythrocytes, granulocytes, and T lymphocytes by a modification" of the procedures described by Sieff et a1."
Briefly, light-density cells (specific gravity < 1.077), not adherent to plastic, were incubated with murine antihuman T lymphocyte (Leu-1 and Leu-5b; Becton Dickinson, Mountain View, CA), Tritiated thymidine suicrde studies.
Clonogenic cultures.
antimonocyte (Leu-MS; Becton Dickinson), and antiglycophorin antibodies (kindly supplied by Dr Richard Langlois, Laurence Livermore Laboratories, Livermore, CA). Then, cells to which IgG had attached were removed by panning in plates coated with goat antimouse IgG (Zymed, San Francisco, CA). Cells were then cultured at a density of 2 to 20 x 103/mL in quadruplicate-culture plates. All culture plates to which GM-CSF was not added also received 20 p,g/mL anti-GM-CSF, and plates to which IL-3 was not added received 20 pgimL anti-IL-3. After 72 hours of culture, E p (2 U/mL) was added to all plates.'* After 14 days of culture, colonies were scored in situ as described previously.
In six of the experiments (three adult and three fetal), individual BFU-E colonies were plucked from plates, placed into a media, repeatedly aspirated, and the cells counted using hemocytometers. In this way the effect of IL-9 on the number of cells per colony was assessed.
Statistical comparisons were performed using the Student's t-test or the Mann-Whitney U-test, as applicable.
Data analysis.
RESULTS
Effect of IL-9 on clonogenic maturation of adult and fetal
BFU-E. In a dose-dependent fashion, IL-9 supported clonogenic maturation of adult and fetal BFU-E (Table 1) . Fewer adult BFU-E colonies formed in response to IL-9 (1.1 ? 0.3/104 cells plated, mean ? SEM) than in response to 1.0 ng GM-CSF/mL (2.5 5 0.2/104, P < .Dol) or to 1.0 ng IL-3/mL (6.3 ? l.2/104, P < .01 v GM-CSF). Addition of IL-9 to plates containing either 0.1 ng or 1.0 ng GM-CSF/mL resulted in more BFU-E colonies. IL-9 also resulted in more BFU-E colonies in plates containing IL-3 or the combination of GM-CSF plus IL-3 (each at 0.1 ng/mL). However, IL-9 did not result in formation of additional adult BFU-E colonies in plates containing the combination of GM-CSF plus IL-3, each at a concentration of 1.0 ng/mL.
As shown in the lower portion of Table 1 , a single agent IL-9 resulted in the formation of as many fetal BFU-E colonies (31.2 ? 3.9/104 cells plated) as did 1.0 ng GM-CSF/mL (27.1 t 2.2/104) or 1 ng IL-3/mL (44.0 -I-7.1/104). An additive effect of IL-9 was observed with GM-CSF and with IL-3. Addition of IL-9 to fetal cells plated in 1.0 ng 
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GM-CSF plus 1.0 ng IL-3/mL resulted in more BFU-E colonies than when GM-CSF and IL-3 were used without IG9.
The effect of IL-9 on the phenotype of BFU-E colonies is shown in Fig 1. The few adult BFU-E colonies (upper panel) that developed in plates containing Epo only (plus neutralizing anti-GM-CSF and anti-IL-3 antibody) were composed of one to three centers. The addition of IL-9 as a single agent to adult cells did not result in formation of multicentered ( 2 10 centers) BFU-E colonies. In contrast, the addition of IL-9 to fetal progenitors (lower panel) altered the BFU-E colony phenotype, with an increase in the proportion of colonies composed of 2 10 individual centers. Addition of IL-9 to adult progenitors stimulated with GM-CSF did not alter the BFU-E colony phenotype, but its addition to fetal progenitors stimulated with GM-CSF resulted in more multicentered BFU-E colonies. In contrast to the adult BFU-E colonies that developed in response to either IL-9 or GM-CSF alone, many that developed in response to IL-3 alone were composed of more than 10 individual centers. Addition of IL-9 resulted in an even greater proportion of multicentered BFU-E colonies. Fetal BFU-E colonies that developed in response to IL3 alone or IL-9 plus IG3 were composed almost exclusively of more than 10 centers.
The influence of IL-9 on the number of cells per BFU-E colony is shown in adult progenitors, no stimulators, and anti-GM-CSF and IL-3 antibody, no CFU-Mix colonies were identified. Few such colonies (0.6 * 0.3/104 plated cells) were observed in cultures of fetal cells. In a dose-dependent fashion, IL-9 supported formation of adult and fetal CFU-Mix colony formation. Its effect was additive to that of GM-CSF but not to that of IL-3. An additive effect of IL-9 to that of GM-CSF plus IL-3 was observed for fetal but not for adult cells.
The effect of IL-9 on CFU-GM colony formation is shown in Table 3 . A small increase in adult CFU-GM colony formation, but a marked increase in fetal CFU-GM colony formation, was observed when IL-9 was used as a single agent. With adult cells, no additive effect of IL-9 with GM-CSF or IL-3 on CFU-GM colony formation was observed. In contrast, with fetal cells additive effects with GM-CSF (0.1 ng/mL only), IL-3, and the combination of GM-CSF and IL-3 (both low and high concentrations) were seen. Figure 3 shows the result of tritiated thymidine suicide studies of adult (upper panel) and fetal (lower panel) cells after incubation with either control (mock-COS), IL-6, or IL-9. Incubation with IL-6 resulted in increased susceptibility of BFU-E, CFU-Mix, Effect of ZL-9 on cycle status.
and CFU-GM to tritiated thymidine of high specific activity. The tritiated thymidine suicide of progenitors incubated with IL-9 was generally intermediate between the low values seen after control incubations and the higher values seen after IL-6 incubation. Increasing the concentration of IL-9 from 0.2 to 20 U/mL had no effect on the thymidine suicide rate.
DISCUSSION
Proliferation and clonal maturation of hematopoietic progenitor cells occur under the influence of hematopoietic growth and differentiation-inducing factor^.'^ Although many such factors have been cloned and their in vitro and in vivo actions examined, other factors probably remain to be characterized. For instance, Yang et al' recently identified a novel human cytokine, IL-9, which they proposed might play a role in hematopoiesis. To test that hypothesis, the present studies were performed in which the effect of IL-9 on clonogenic maturation and cycling status of fetal and adult hematopoietic progenitors was assessed.
We observed that IL-9 supported clonogenic maturation of fetal and adult BFU-E in a concentration-dependent fashion. The number of fetal BFU-E colonies arising after stimulation with IL-9 was similar to the number arising after stimulation with plateau concentrations of GM-CSF, and comparable with the number after IL-3. In contrast, IL-9 supported only about '/3 of the adult BFU-E colonies arising after stimulation with GM-CSF and about '/b of the colonies arising after stimulation with IL-3. Using fetal cells, IL-9 was synergistic with both low (0.1 ng/mL) and high (1.0 ng/mL) concentrations of GM-CSF and IL-3, and also supported CFU-Mix and CFU-GM colonies. In contrast, no effect of IL-9 was apparent in cultures of adult cells containing high concentrations of both GM-CSF and IL-9 affected the phenotype of fetal BFU-E colonies, resulting in generation of colonies with more individual centers and containing more cells. Studies by Eaves and Eaves14 and Sieff et allz suggest that BFU-E which generate colonies containing 210 centers are more resistent to tritiated thymidine of high specific activity and appear later in culture than do BFU-E which generate colonies composed of few centers. Thus, perhaps IL-9 supports clonal maturation of a primitive subset of fetal BFU-E.
In previous studies' as well as in the present experiments, incubating progenitors with IL-6 resulted in induction of a portion of the progenitors into S phase. This is consistent with the postulate of Ikebuchi et aI,l5 that the action of IL-6 on hematopoietic progenitors is to enhance proliferation of early progenitors, and not to support terminal differentiation. In the present studies, incubation with IL-9 did not induce progenitors into S phase to the extent observed after incubation with IL-6. This difference and the effect of IL-9, along with Epo, on supporting terminal differentiation of BFU-E distinguish the hematopoietic effects of IL-9 and Even though anti-IL-3 and anti-GM-CSF neutralizing antibody were included in the cultures and "accessory cells" were depleted before plating, it cannot be concluded that the actions of IL-9 which we observed were all direct actions on progenitors. In a manner similar to the in vitro hematopoietic actions of IL-1,16 the effects we observed might have been mediated through changes in production of other growth factors by residual accessory cells or clonally derived cells within the cultures.
Many of the hematopoietic actions of IL-9 in vitro overlap with those of IL-3 and GM-CSF. However, its spectrum of action appears to be unique. Specifically, like IL-3',17,'8 and GM-CSF,9,'7 IL-9 supports clonal maturation of BFU-E. In cultures of fetal cells stimulated with GM-CSF or IL-3, the addition of IL-9 results in formation of more colonies and more cells per BFU-E colony than are found using GM-CSF or IL-3 alone. Also, in cultures of fetal cells IL-9 supports maturation of CFU-Mix and CFU-GM. Thus, as has previously been demonstrated with Epo6.* and IL-6: IL-9 has a wider spectrum of action on fetal than adult progenitors. The mechanism responsible for this wider spectrum of action and the physiologic role of IL-9 in regulation of hematopoiesis remain to be determined.
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